Psychedelic Drug Fast-Tracked Despite 27 Deaths

Magnifying glass focusing on a skull and crossbones symbol against a red background — DEADLY DRUG FAST-TRACKED

President Trump signed an executive order accelerating research into psychedelic drugs, including ibogaine, a controversial substance linked to 27 deaths, raising questions about whether politics is overtaking science in the rush to address America’s mental health crisis.

Story Snapshot

Trump’s April 18, 2026, executive order commits $50 million to fast-track psychedelic research for PTSD, addiction, and mental illness
Order specifically emphasizes ibogaine despite cardiac toxicity risks and absence of Phase I safety trials
FDA and DEA directed to create Right to Try pathways for terminally ill patients to access these Schedule I drugs
Critics warn the move prioritizes political promises to veterans over rigorous medical science

Federal Funding Pushes Controversial Treatment Forward

President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate research into psychedelic drugs for treating serious mental illness. The order allocates $50 million through ARPA-H to match state investments in psychedelic research, with particular focus on substances like ibogaine, psilocybin, LSD, and MDMA.

The White House framed the initiative as a scientific response to a national crisis affecting more than 14 million Americans with serious mental illness, particularly veterans suffering from PTSD and traumatic brain injuries who have exhausted traditional treatment options.

The order instructs the FDA and DEA to establish access pathways under the Right to Try Act for eligible patients, removing legal barriers to research without reclassifying these Schedule I substances. This represents a significant shift in federal policy toward psychedelics, which have been classified alongside heroin and ecstasy since the 1970s.

Trump administration officials stated they aim to determine whether ibogaine is legitimate medicine or “snake oil,” acknowledging the experimental nature of the initiative while emphasizing urgency in addressing veterans’ needs.

Cardiac Risks Shadow Ibogaine’s Promise

Ibogaine, derived from an African shrub traditionally used in Bwiti rituals, has attracted attention for its potential to interrupt addiction cycles. However, a 2023 review of 24 studies involving 705 people documented 27 deaths linked to the substance, primarily from cardiac complications including QT prolongation and arrhythmias.

The drug remains illegal in the United States, forcing Americans to seek treatment at unregulated clinics in Mexico and the Caribbean where proper heart screening and monitoring are frequently absent. Medical experts identify cardiotoxicity as the primary barrier to ibogaine’s acceptance, a risk that NIDA Director Nora Volkow specifically flagged in 2024.

Trump signs order to speed review of psychedelics, including the controversial drug ibogainehttps://t.co/1ndcZ6JYjv pic.twitter.com/QRget6qwpP

— 1010 WINS on 92.3 FM (@1010WINS) April 18, 2026

A July 2024 Stanford study offered more promising results, finding that ibogaine combined with magnesium appeared safe for veterans with PTSD and depression. Yet this research lacked a placebo control group, an essential feature of rigorous medical testing.

Harvard legal analysts Glenn Cohen and Mason Marks expressed surprise at the executive order’s emphasis on ibogaine given its lack of Phase I safety trials, noting that other psychedelics like MDMA have advanced much further through the FDA approval process.

The decision to highlight ibogaine appears driven by veteran advocacy groups and state initiatives like Texas’s 2025 ibogaine research consortium rather than scientific readiness.

Right to Try Meets Political Reality

The executive order leverages Trump’s 2018 Right to Try Act, originally designed to give terminally ill patients access to experimental treatments. However, applying this framework to psychedelics that haven’t completed Phase I safety trials represents uncharted territory.

The FDA will prioritize reviews of psychedelics receiving Breakthrough Therapy designation, while the DEA must facilitate research access despite these substances remaining Schedule I controlled substances.

This approach attempts to thread the needle between maintaining legal restrictions and enabling research, though critics argue it puts political expediency ahead of the systematic safety validation that protects patients from harm.

Texas’s decision to fund an ibogaine research consortium in 2025 provided momentum for federal action, demonstrating how state-level initiatives can influence national policy. The $50 million in matching federal funds will accelerate these state efforts, potentially establishing protocols for safe use if clinical trials succeed.

Yet the fundamental tension remains: psychedelics may fill critical gaps in treating addiction and PTSD where conventional medicine has failed, but rushing unproven treatments to market risks repeating past pharmaceutical disasters.

For Americans frustrated with government dysfunction, this executive order exemplifies the dilemma—leadership willing to take action versus institutional safeguards designed to prevent catastrophic mistakes.

Government Gambles With Veterans’ Lives

This executive order reveals a troubling pattern where political calculations override scientific rigor. More than 14 million Americans suffer from serious mental illness, and traditional treatments have demonstrably failed many veterans.

That desperation creates pressure for government action, but using executive authority to fast-track a drug linked to 27 deaths without completed safety trials represents a dangerous precedent.

Whether motivated by genuine compassion for veterans or political positioning, the result is the same: vulnerable patients may gain access to treatments before science has adequately determined if they help or harm.

The federal government’s proper role should be removing bureaucratic obstacles to legitimate research while maintaining safety standards, not gambling with citizens’ lives to demonstrate responsiveness to constituents’ suffering.